PL2968650T3 - Preparaty do oczu do dostarczania leku do tylnego fragmentu oka - Google Patents

Preparaty do oczu do dostarczania leku do tylnego fragmentu oka

Info

Publication number
PL2968650T3
PL2968650T3 PL14724204T PL14724204T PL2968650T3 PL 2968650 T3 PL2968650 T3 PL 2968650T3 PL 14724204 T PL14724204 T PL 14724204T PL 14724204 T PL14724204 T PL 14724204T PL 2968650 T3 PL2968650 T3 PL 2968650T3
Authority
PL
Poland
Prior art keywords
eye
drug
delivery
posterior segment
ocular formulations
Prior art date
Application number
PL14724204T
Other languages
English (en)
Inventor
David P. Bingaman
Paul G. Chaney
Martin B. Wax
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of PL2968650T3 publication Critical patent/PL2968650T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14724204T 2013-03-14 2014-03-14 Preparaty do oczu do dostarczania leku do tylnego fragmentu oka PL2968650T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784681P 2013-03-14 2013-03-14
EP14724204.4A EP2968650B1 (en) 2013-03-14 2014-03-14 Ocular formulations for drug-delivery to the posterior segment of the eye
PCT/US2014/027589 WO2014152661A1 (en) 2013-03-14 2014-03-14 Ocular formulations for drug-delivery to the posterior segment of the eye

Publications (1)

Publication Number Publication Date
PL2968650T3 true PL2968650T3 (pl) 2019-05-31

Family

ID=50625096

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14724204T PL2968650T3 (pl) 2013-03-14 2014-03-14 Preparaty do oczu do dostarczania leku do tylnego fragmentu oka

Country Status (23)

Country Link
US (7) US9446026B2 (pl)
EP (2) EP3520773A1 (pl)
JP (3) JP6542193B2 (pl)
KR (2) KR20210132205A (pl)
CN (2) CN105142686B (pl)
AU (3) AU2014239252B2 (pl)
BR (1) BR112015021334B1 (pl)
CA (1) CA2900840C (pl)
DK (1) DK2968650T3 (pl)
ES (1) ES2710152T3 (pl)
HK (1) HK1216236A1 (pl)
HU (1) HUE042528T2 (pl)
IL (2) IL240510B (pl)
MX (1) MX360888B (pl)
PH (2) PH12015501938B1 (pl)
PL (1) PL2968650T3 (pl)
PT (1) PT2968650T (pl)
RU (2) RU2665953C2 (pl)
SA (1) SA516380321B1 (pl)
SG (2) SG10201710928PA (pl)
TR (1) TR201901462T4 (pl)
WO (1) WO2014152661A1 (pl)
ZA (2) ZA201505447B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965828T3 (es) 2012-09-12 2024-04-17 Novaliq Gmbh Composiciones de alcano semifluorado
PT3193867T (pt) * 2014-09-17 2021-03-09 Panoptica Inc Formulações oculares para administração de fármaco e proteção do segmento anterior do olho
EP3355990B1 (en) 2015-09-30 2019-06-12 Novaliq GmbH Semifluorinated compounds and their compositions
US10155360B2 (en) 2016-03-11 2018-12-18 Georgia-Pacific Gypsum Llc Gypsum panels, systems, and methods
EP3612228B1 (en) * 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
RU2652342C1 (ru) * 2017-07-13 2018-04-25 Наталья Александровна Гаврилова Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AT522609B1 (de) 2019-05-28 2022-06-15 Miba Frictec Gmbh Reibvorrichtung
EP4334360A2 (en) 2021-05-03 2024-03-13 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891913A (en) 1994-10-10 1999-04-06 Novartis Finance Corporation Ophthalmic and aural compositions containing diclofenac potassium
JPH10203960A (ja) * 1997-01-24 1998-08-04 Ofutekusu:Kk 点眼液組成物
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
JP4682495B2 (ja) * 1999-09-06 2011-05-11 小野薬品工業株式会社 眼疾患の予防、治療剤
CN1231474C (zh) * 2000-11-28 2005-12-14 辉瑞产品公司 异噻唑-4-羟酰胺的盐及其作为抗过度增殖剂的用途
MXPA05000950A (es) 2002-07-25 2005-05-16 Pfizer Prod Inc Derivados de isotiazol utiles como agentes anticancerosos.
AU2003211555A1 (en) * 2002-08-29 2004-03-29 Kistem Co., Ltd Vision aid network server, vision aid network system, vision aid method, vision aid system, color sense function reporting system, program for reporting color sense function, method for reporting color sense function, color sense aid system, color sense aid program, and color sense aid method
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
US7483533B2 (en) * 2004-08-05 2009-01-27 King Fahd University Of Petroleum Elliptic polynomial cryptography with multi x-coordinates embedding
JP2006111621A (ja) * 2004-09-15 2006-04-27 Santen Pharmaceut Co Ltd ピレノキシン懸濁型点眼剤
KR101319772B1 (ko) * 2004-11-09 2013-10-23 노바갈리 파르마 에스 에이 면역 억제제를 포함하는 안과용 유제
WO2006133411A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
JP2007012937A (ja) * 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
JP2007011785A (ja) * 2005-06-30 2007-01-18 Toshiba Corp 情報処理装置、およびタッチパネルの振動制御方法
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ATE479424T1 (de) * 2005-10-10 2010-09-15 Novagali Pharma Sa Prostaglandine enthaltende ophthalmische emulsionen
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
AU2008218783A1 (en) * 2007-02-22 2008-08-28 Colby Pharmaceutical Company Hydroxylamine compounds and methods of their use
JP5276591B2 (ja) * 2007-08-09 2013-08-28 千寿製薬株式会社 ピレノキシン含有二液性点眼剤
JP2010265261A (ja) * 2009-04-17 2010-11-25 Santen Pharmaceut Co Ltd レボカバスチン懸濁型点眼剤
JP2012250918A (ja) * 2011-05-31 2012-12-20 Rohto Pharmaceutical Co Ltd ニューキノロン剤含有水性組成物
EP2817031A4 (en) 2012-02-22 2015-08-05 Tufts College COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT

Also Published As

Publication number Publication date
JP6542193B2 (ja) 2019-07-10
SA516380321B1 (ar) 2019-01-16
AU2014239252B2 (en) 2017-07-06
ZA201505447B (en) 2022-06-29
KR20150127256A (ko) 2015-11-16
CA2900840A1 (en) 2014-09-25
MX2015012653A (es) 2016-08-18
PH12015501938A1 (en) 2016-01-11
US20190247368A1 (en) 2019-08-15
WO2014152661A1 (en) 2014-09-25
IL240510B (en) 2020-08-31
BR112015021334B1 (pt) 2020-04-07
SG11201507316UA (en) 2015-10-29
IL276016A (en) 2020-08-31
US20160022646A1 (en) 2016-01-28
AU2014239252A1 (en) 2015-08-13
US20190183864A1 (en) 2019-06-20
US10092549B2 (en) 2018-10-09
RU2768489C2 (ru) 2022-03-24
JP2022009275A (ja) 2022-01-14
AU2019202857A1 (en) 2019-05-16
CA2900840C (en) 2023-03-28
BR112015021334A2 (pt) 2017-07-18
ES2710152T3 (es) 2019-04-23
HK1216236A1 (zh) 2016-10-28
IL240510A0 (en) 2015-10-29
US20210196690A1 (en) 2021-07-01
RU2015143898A (ru) 2017-04-19
US20140303219A1 (en) 2014-10-09
EP2968650A1 (en) 2016-01-20
CN105142686A (zh) 2015-12-09
MX360888B (es) 2018-11-20
AU2019202857B2 (en) 2021-02-18
DK2968650T3 (en) 2019-03-11
RU2018128980A3 (pl) 2022-01-11
JP2019167377A (ja) 2019-10-03
ZA201907176B (en) 2022-12-21
EP2968650B1 (en) 2019-01-16
HUE042528T2 (hu) 2019-07-29
EP3520773A1 (en) 2019-08-07
US20190240201A1 (en) 2019-08-08
JP6965308B2 (ja) 2021-11-10
CN105142686B (zh) 2020-04-10
US20160354349A1 (en) 2016-12-08
PH12019501902A1 (en) 2021-03-01
RU2018128980A (ru) 2018-11-05
IL276016B (en) 2022-04-01
US10307404B1 (en) 2019-06-04
RU2665953C2 (ru) 2018-09-05
SG10201710928PA (en) 2018-02-27
US9446026B2 (en) 2016-09-20
CN111789814A (zh) 2020-10-20
CN111789814B (zh) 2022-07-19
AU2017210543A1 (en) 2017-08-17
JP2016517427A (ja) 2016-06-16
AU2017210543B2 (en) 2019-01-31
PH12015501938B1 (en) 2016-01-11
PT2968650T (pt) 2019-02-12
KR102433489B1 (ko) 2022-08-17
KR20210132205A (ko) 2021-11-03
TR201901462T4 (tr) 2019-02-21

Similar Documents

Publication Publication Date Title
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
IL267997A (en) Preparations, formulations and methods for treating eye diseases
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
IL244687A0 (en) Epinephrine-based ophthalmic preparations for intraocular administration and methods for their production
EP2928424A4 (en) SYSTEMS AND METHOD FOR MOISTENING EYES DURING EYE OPERATION
EP3061455A4 (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
IL282504A (en) Ocular formulations for drug administration and protection of the front part of the eye
SG11201506882YA (en) Ophthalmic formulations
HK1221190A1 (zh) 炎症性眼科疾病的局部治療
EP2950782A4 (en) RETARD FORMULATIONS FOR THE TREATMENT OF INTRAOCULAR PRESSURE OR GLAUCOMA
GB2571647B (en) The use of dipropylene/diethylene glycol dibenzoate to reduce eye irritation
GB201303131D0 (en) Ocular prosthesis
GB2520410B (en) Digital applanation tonometer
EP3170500A4 (en) Prophylactic or therapeutic agent for diseases of posterior segment of eye
GB201306413D0 (en) The local treatment of ophthalmic diseases